Download presentation
Presentation is loading. Please wait.
Published byRudolph Baldwin Modified over 8 years ago
1
Urinary Incontinence in Women Dr Mangala Dissanayake
2
OBJECTIVES Identify the various forms of Urinary Incontinence (UI) in females To become knowledgeable about the treatment interventions available To understand the impact of Urinary Incontinence
4
Prevalence of Urinary Incontinence 33% of women >65 have some degree of UI 26% of women>18 experience various degree of SI 15% to 30% of non-institutionalized older adults (19% men; 39% women) Prevalence increases with age and Menopause Incidents are more in female until the age of 80
5
Prevalence of UI
6
Incontinence in women – 19 billion dollars / yr “Silent Epidemic” Epidemiology
7
Urinary Incontinence is Often Under-Diagnosed and Under-Treated Only 32% of primary care physicians routinely ask about incontinence. 50-75% of patients never describe symptoms to physicians 80% of urinary incontinence can be cured or improved.
8
Definition UI is the involuntary loss of urine that is objectively demonstrable and a social or hygienic problem. International Continence Society
9
Risk and Contributing Factors Age Parity Obesity Vaginal delivery Episiotomy ? Diabetes, BA, Chronic constipation Stroke Estrogen depletion Genitourinary surgery and radiation Depression,Dementia, Parkinson
10
Health Burden
11
Age and Menopause Detrusor overactivity (20% of healthy continent) PVR, nocturia, UO later in day Atrophic vagintis & urethritis ability to postpone voiding, total bladder capacity, detrusor contractility urine concentrating ability, flow
12
Consequences of UI Cellulitis, Pressure ulcers, UTI Sexual Problems Falls with fractures Sleep deprivation Social withdrawal, depression Embarrassment (50%), interference with activities Caregiver burden, contributes to institutionalization Costs
13
Types of UI Transient UI (Acute) Established UI (Chronic) Urge UI Stress UI Mixed UI Overflow UI “Functional” UI
14
Prevalence in women Stress : 49% Urge : 22% Mixed : 29%
15
Transient UI (Acute) Lower urinary tract pathology Precipitated by reversible factors Causes: Delirium, UTI, Medications, Psychiatric disorders, Stool impaction Restricted mobility
16
Causes for Transient UI D Delirium I Infection A Atrophic Vulvovaginitis P Psychological P Pharmacologic agents E Endocrine, excessive UO R Restricted Mobility S Stool impaction
17
sedatives loop diuretics alcohol caffeine cholinergics (donepezil) awareness, detrusor activity Func & O UI Diuresis overwhelms bladder capacity Urge & O UI Polyuria, awareness Urge & Functional UI Polyuria, detrusor activity Urge detrusor activity Urge Culligan PJ Urinary Incontinence in women Evaluation and Management AFP 12-1-01 Pharmacologic Causes
18
Physiology
20
Stress Urinary incontinence Involuntary loss of urine due to increase abdominal pressure without Detrusor contraction
21
Stress incontinence
22
STRESS INCONTINENCE Most common type in women in < 75 years old Occurs with increase in abdominal pressure- cough, laugh, sneeze, etc Hyper motility of bladder neck and urethra associated with aging, child birth, hormonal changes Intrinsic sphincter problems( pelvic irradiation, surgery, trauma, incontinence surgery) No urgency or nocturia
23
Treatment : Stress Incontinence Nonsurgical – Pelvic floor muscle training (Kegel’s) – Biofeedback – Electrical stimulation – Pessaries – Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor.
24
Non Surgical Modest improvements – Pt’s with a small amount of leakage – Pt’s who want a conservative trial – Pt’s with significant comorbidities
25
Duloxetine Combined serotonin and noradrenaline reuptake inhibitor
26
Mechanism of action Increased synaptic concentration of noradrenaline and 5-hydroxytryptamine within the pudendal nerve results in increased stimulation of urethral striated muscles within the sphincter thus enhancing contraction. Increase sphincter activity in the storage phase of the micturition cycle
28
Authors’ conclusions Duloxetine Duloxetine treatment can significantly improve the quality of life of patients with stress urinary incontinence, but it is unclear whether or not benefits are sustainable Adverse effects are common but not serious. About one in three participants allocated duloxetine reported adverse effects (most commonly nausea) related to treatment, and One in eight allocated duloxetine stopped treatment as a consequence.
29
Authors’ conclusions Duloxetine Better than placebo Improved QOL May improve outcome in combination with pelvic floor training- Ghoniem 2005
30
Surgery A Burch Colposuspension C Tension-free Vaginal Tape B Fascial Sling
31
Stress Urinary Incontinence Less Invasive Surgery: Trans-obturator Tapes Anatomical landmarks Tape passes through medial edge of obturator foramen just below the insertion of the adductor longus tendon
32
Priurethral Injection for SUI
33
Objective cure rates for first procedure and recurrent incontinence 6 Stress Urinary Incontinence Surgical Treatment: Cure Rates
34
Urge Incontinence Incontinence accompanied by or immediately preceded by urinary urgency
35
Urge incontinence
37
URGE INCONTINENCE OAB, Detrusor instability, irritable bladder, detrusor hyperactivity. Most common UI > 75 years of age Abrupt desire to void urine cannot be suppressed Associated with frequency / nocturia. Causes- infection, vaginitis, tumor, stones, idiopathic ( Hormonal)
38
Urge incontinence
39
URGE INCONTINENCE
40
URGE INCONTINENCE Treatment Patient education Timed voiding Habit training urge inhibition bladder training Diet modification Surgery Local Oestrogen
41
URGE INCONTINENCE Treatment- Anticholinergic Drugs Oxybutynin Tolterodine Trospium Darifenacin Variety of preparations: Immediate Release; Extended Release; Transdermal Outcomes same; Try different agent if one doesn’t work. Continue for at least 4 weeks ***** ALL these drugs suppress the detrusor contractility and MAY CAUSE URINARY RETENTION!!! ALWAYS CHECK PVR PRIOR TO PRESCRIBING!!!
42
Antimuscarinic therapy
43
Side Effects 43%–83% of women abandon antimuscarinic therapy by 1 month At 1 year-35% women are still taking the medication
44
Mirabegron Beta-3 adrenoreceptor agonist Promotes relaxation of the detrusor muscle – Reduce incontinence episodes – Reduced urgency – Reduced frequency Vs placebo (pooled data of 3 phase III RCTs) US Food and Drug Administration (FDA) approved in 2012
45
HRT and UI Conclusion At present, systemic HRT administration should not be recommended for treatment or prevention of UI in postmenopausal, especially older, women. Urinary incontinence may be improved with the use of local oestrogen treatment
46
URGE INCONTINENCE Refractory to Treatment
47
OVERFLOW INCONTINENCE Over Distension of Bladder Bladder outlet obstruction- Stricture, Cystocele, fecal impaction Non contractile bladder- Diabetes, Spinal injury. Filling occurs to the stretch limit of the bladder Large PVR >400cc Dribbling, frequency High rates of infections
49
Pessary
50
OVERFLOW INCONTINENCE Obstruction—Treat cause; -antagonist- Tamsulosin, Prazosin Detrusor Underactivity intermittent self- catheterization Bethanechol ( used to treat underactive detrusor function with elevated PVR) Patient education “Double voiding technique” Diet modification Avoid caffeine/alcohol Barrier product to prevent skin breakdown Reassess the Medication
51
OVERFLOW INCONTINENCE Tamsulosin Efficacy and Safety of Tamsulosin for the Treatment of Non- neurogenic Voiding Dysfunction in Females: A 8-Week Prospective Study Tamsulosin was found to be effective in female patients with voiding dysfunction regardless of obstruction grade.
52
Tamsulosin Vs Prazosin in OI Tamsulosin and prazosin are both effective in palliating symptoms of women with voiding dysfunction and improving their urodynamic parameters. Tamsulosin may be the preferred drug to prescribe because of its more amenable side effect profile and greater patient satisfaction.
53
Features of both urge and stress incontinence. Common in older women 4-55% mixed type of UI Management: bladder retraining, pelvic muscle exercises, Diet Modifications pharmacologic agents- Antichloinergic, Imipramine Mixed Incontinence
54
MIXED INCONTINENCE
55
“Functional” Incontinence Unable or unwilling to toilet due to physical impairment, cognitive dysfunction, environmental barriers No underlying GU dysfunction Diagnosis of exclusion
56
EVALUATION OF INCONTINENCE History Physical exam ( including Neuro and abdominal, pelvic and rectal examination) Clinical testing- Stress test, PVR by catheterization or ultrasound. Laboratory testing- UA, Urine culture, FBS,B Urea. URODYNAMIC TESTING
59
Cesarean Section Vs UI Pregnancy per se increases UI, irrespective of mode of delivery Elective/ Pre labour Cesarean section has low incidents of UI in Post partum period Advantage disappears with age and in subsequent pregnancies
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.